Yarchoan Discusses Sequencing Treatment Options for Patients With HCC
Mark Yarchoan, MD, explains his method for sequencing available treatment options for patients with hepatocellular carcinoma.<br />
Mark Yarchoan, MD, medical oncologist, John Hopkins Medicine, explains his method for sequencing available treatment options for patients with hepatocellular carcinoma (HCC).
There is no correct answer to the question of what the best second-line treatment is for HCC. This is because more data are needed on most of the available agents. Previously, many of these drugs were studied when the only first-line drug available was sorafenib (Nexavar).
Immunotherapy will continue to play some role in the treatment of HCC because there is a group of patients who respond well to antiPD-1 therapy and some can have disease control for years. The majority of patients, however, do not respond to anti–PD-1 therapy, so it should only be considered for patients who progress on first-line therapy and are reluctant to take another tyrosine kinase inhibitor because of toxicity.
Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC
December 21st 2024During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the limited available trial data for treating patients with unresectable hepatocellular carcinoma with Child-Pugh B status.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
